NVST Envista Holdings Corporation

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the dental equipment & technology industry, including Envista (NYSE:NVST) and its peers.

VG, HCSG, NVST, EQNR and HMN have been added to the Zacks Rank #1 (Strong Buy) List on September 28, 2026.

NVST vs. ABT: Which Stock Is the Better Value Option?

Envista Holdings (NVST) is set to present at the 2026 Global Healthcare Conference in New York on September 15, giving investors fresh commentary to weigh against recent share performance and fundamentals. Envista Holdings enters the conference with mixed momentum, with the share price up 8.02% year to date but a 30 day share price return down 13.86%, and longer term total shareholder returns of 12.16% over one year and a decline of 44.86% over five years. Compare Envista Holdings with a...

SLDE, HHH and NVST made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 21st, 2026.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Envista (NVST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

NVST vs. ABT: Which Stock Is the Better Value Option?

XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Envista Holdings Corp. (NYSE:NVST) shares rose 2.

Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls

Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Envista Holdings arrives at a tricky valuation point for investors, with an intrinsic value estimate from a Discounted Cash Flow (DCF) suggesting the stock may trade below its underlying cash flow value, while market based multiples make the shares look more expensive and the broader checklist does not flag a clear bargain. Over the past 5 years the stock has fallen 38.0%, which leaves long term holders with a weak result and puts extra focus on whether the current price reflects realistic...

MDT beats Q1 earnings and revenue estimates as broad-based growth drives shares higher and prompts a fiscal 2027 guidance boost.

Dollar General, Envista, Match Group and Allstate stand out as PEG-based value picks as investors seek opportunities beyond AI stocks.

Four value stocks stand out as investors look beyond AI, using PEG ratios, earnings growth and valuation metrics to find potential winners.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

ONTO, VIRT and NVST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 27th, 2026.

NVST, VIRT, ONTO, HMN and PROV have been added to the Zacks Rank #1 (Strong Buy) List on August 27th, 2026.

VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.

Over the past six months, Envista’s shares (currently trading at $27.36) have posted a disappointing 7.6% loss, well below the S&P 500’s 10.5% gain. This may have investors wondering how to approach the situation.

Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

NVST vs. ABT: Which Stock Is the Better Value Option?

Investors need to pay close attention to NVST stock based on the movements in the options market lately.

ZIM, FHI and NVST made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 24th, 2026.

Envista Holdings (NVST) has combined its top leadership roles, with President and Chief Executive Officer Paul Keel also appointed Chair of the Board as of 19 August 2026, while Scott Huennekens becomes Lead Independent Director. See our latest analysis for Envista Holdings. Envista Holdings shares trade at US$26.93 after a recent 1 day share price return that declined 2.36%, although the 90 day share price return of 14.94% and 1 year total shareholder return of 31.62% indicate momentum has...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Envista , Reliance, The Ensign, The Hanover Insurance and Lenovo have been highlighted in this Screen of The Week article.

Stocks like NVST, RS, THG and LNVGY are seeing price strength and have a high chance of carrying the momentum forward.

ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.

Envista raises 2026 guidance as stronger sales and expanding margins lift earnings, but China pricing, tariffs and a tougher Q4 loom.

Envista’s second quarter results were shaped by balanced growth across all major geographies and a continued focus on operational execution. Management pointed to resilient demand for dental care, especially in consumables and diagnostics, as a stabilizing influence despite macroeconomic uncertainty. CEO Paul Keel highlighted that new product launches in endodontics and orthodontics supported share gains, while margin expansion was driven by manufacturing productivity and cost control initiative

Envista's earnings rebound and raised 2026 guidance strengthen the case, but above-median valuation leaves less room for execution setbacks.

Margins expanded 230 basis points as core growth accelerated.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

PEG-focused value picks Envista, Sanmina, TAL Education and Avient combine discounted valuations with solid long-term growth prospects.

Four value stocks stand out for low PEG ratios, strong earnings growth prospects and favorable value scores, offering potential beyond traditional P/E screens.

AVT, GEO and NVST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 10, 2026.

Examine the evolution of Envista's (NVST) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

VRT, NVST, and AER it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 10, 2026.

Envista Holdings Corporation recently reported Q2 2026 results showing higher sales of US$730.5 million and net income of US$53.7 million, with earnings per share from continuing operations rising to US$0.33. Alongside these results, Envista completed share repurchases totaling 12,458,894 shares for US$250 million, while also raising its full-year 2026 guidance despite expected pricing pressure in China. Now we will examine how Envista’s raised full-year guidance and earnings momentum...

Envista (NYSE:NVST) reported second-quarter 2026 sales of $731 million, supported by 5% core revenue growth and contributions from foreign exchange and acquisitions that lifted total revenue growth to just over 7%. President and Chief Executive Officer Paul Keel said the company delivered balanced

NVST vs. ABT: Which Stock Is the Better Value Option?

Moby summary of Envista Holdings Corp's Q2 2026 earnings call

Envista Holdings Corp (NVST) delivered 5% core sales growth and raised its full-year 2026 outlook, driven by broad-based segment gains and operational efficiency.

Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.